Cargando…

Tocilizumab in the Treatment of Chronic Antibody-Mediated Rejection Post Kidney Transplantation: Clinical and Histological Monitoring

Introduction: Chronic antibody-mediated rejection (cAMR) has very few effective therapeutic options. Interleukin-6 is an attractive target because it is involved in inflammation and humoral immunity. Therefore, the use of tocilizumab (anti-IL6 receptor, TCZ) is a potential valuable therapeutic optio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noble, Johan, Giovannini, Diane, Laamech, Reda, Imerzoukene, Farida, Janbon, Bénédicte, Marchesi, Laura, Malvezzi, Paolo, Jouve, Thomas, Rostaing, Lionel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8739887/ https://www.ncbi.nlm.nih.gov/pubmed/35004757 http://dx.doi.org/10.3389/fmed.2021.790547

Ejemplares similares

Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review
por: Cabezas, Lara, et al.
Publicado: (2022)

Very Early Severe Posttransplant Recurrent Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis after Kidney Transplantation: Two Case Reports
por: Laamech, Reda, et al.
Publicado: (2022)

Tocilizumab Evaluation in HLA-Desensitization before Kidney Transplantation as an Add-On Therapy to Apheresis: The TETRA Study
por: Jouve, Thomas, et al.
Publicado: (2023)

Conversion to mTOR-Inhibitors Plus IV Immunoglobulins in Kidney-Transplant Recipients with BKV Infection: A Retrospective Comparative Study
por: Vela, Carla, et al.
Publicado: (2022)

Protocol Biopsies on de novo Renal-Transplants at 3 Months after Surgery: Impact on 5-Year Transplant Survival
por: Terrec, Florian, et al.
Publicado: (2021)

Tocilizumab and Desensitization in Kidney Transplant Candidates: Personal Experience and Literature Review
por: Weinhard, Jules, et al.
Publicado: (2021)

Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters
por: Terrec, Florian, et al.
Publicado: (2019)

Belatacept Use after Kidney Transplantation and Its Effects on Risk of Infection and COVID-19 Vaccine Response
por: Terrec, Florian, et al.
Publicado: (2021)

Apheresis Efficacy and Tolerance in the Setting of HLA-Incompatible Kidney Transplantation
por: Noble, Johan, et al.
Publicado: (2021)

Early Exposure of Kidney Transplant Recipients with Chronic Antibody-Mediated Rejection to Tocilizumab—A Preliminary Study
por: Arrivé, Capucine, et al.
Publicado: (2023)

Tocilizumab Trough Levels Variability in Kidney-Transplant Candidates Undergoing Desensitization
por: Truffot, Aurélie, et al.
Publicado: (2021)

Marginal Impact of Tocilizumab Monotherapy on Anti-HLA Alloantibodies in Highly Sensitized Kidney Transplant Candidates
por: Daligault, Mélanie, et al.
Publicado: (2021)

Transplantation of Marginal Organs: Immunological Aspects and Therapeutic Perspectives in Kidney Transplantation
por: Noble, Johan, et al.
Publicado: (2020)

Immortal Time-Bias–Corrected Survival of Highly Sensitized Patients and HLA-desensitized Kidney Transplant Recipients
por: Noble, Johan, et al.
Publicado: (2021)

Costimulation Blockade in Kidney Transplantation: An Update
por: Malvezzi, Paolo, et al.
Publicado: (2016)

Kidney Transplantation for Focal Segmental Glomerulosclerosis: Can We Prevent Its Recurrence? Personal Experience and Literature Review
por: Naciri Bennani, Hamza, et al.
Publicado: (2021)

Place of mTOR inhibitors in management of BKV infection after kidney transplantation
por: Jouve, Thomas, et al.
Publicado: (2016)

Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage
por: Malvezzi, Paolo, et al.
Publicado: (2015)

Negative Impact of CMV and BKV Infections on Kidney-Allograft Function at 1-Year Post-Transplantation: Can it Be Changed by Modifying Immunosuppression?
por: Malvezzi, Paolo, et al.
Publicado: (2018)

Apheresis Therapy for Steroid-Resistant Idiopathic Nephrotic Syndrome: Report on a Case Series
por: Naciri Bennani, Hamza, et al.
Publicado: (2019)

Early Blood Transfusion After Kidney Transplantation Does Not Lead to dnDSA Development: The BloodIm Study
por: Jouve, Thomas, et al.
Publicado: (2022)

Efficacy of Plasmapheresis in Nivolumab-Associated ANCA Glomerulonephritis: A Case Report and Pathophysiology Discussion
por: Laamech, Reda, et al.
Publicado: (2021)

Cryoglobulinemia and double‐filtration plasmapheresis: Personal experience and literature review
por: Naciri Bennani, Hamza, et al.
Publicado: (2022)

An Atypical Case of Shiga Toxin Producing-Escherichia Coli Hemolytic and Uremic Syndrome (STEC-HUS) in a Lung Transplant Recipient
por: Manière, Louis, et al.
Publicado: (2019)

Opportunistic Infections and Efficacy Following Conversion to Belatacept-Based Therapy after Kidney Transplantation: A French Multicenter Cohort
por: Bertrand, Dominique, et al.
Publicado: (2020)

Steroid-Based Therapy and Risk of Infectious Complications
por: Rostaing, Lionel, et al.
Publicado: (2016)

Post-Transplant Surveillance and Management of Chronic Active Antibody-Mediated Rejection in Renal Transplant Patients in Europe
por: Rostaing, Lionel P. E., et al.
Publicado: (2023)

Immune Response Post–SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Receiving Belatacept
por: Noble, Johan, et al.
Publicado: (2021)

Efficacy and Safety of Tocilizumab in the Treatment of Acute Active Antibody-mediated Rejection in Kidney Transplant Recipients
por: Pottebaum, April A., et al.
Publicado: (2020)

Safety and efficacy of eculizumab for the prevention of antibody‐mediated rejection after deceased‐donor kidney transplantation in patients with preformed donor‐specific antibodies
por: Glotz, Denis, et al.
Publicado: (2019)

Atypical Evolution of Secondary Hemolytic Uremic Syndrome Defined as Paraneoplastic Syndrome under Eculizumab and Palbociclib Therapies
por: Perrier, Quentin, et al.
Publicado: (2021)

A Prospective Multicenter Trial to Evaluate Urinary Metabolomics for Non-invasive Detection of Renal Allograft Rejection (PARASOL): Study Protocol and Patient Recruitment
por: Banas, Miriam C., et al.
Publicado: (2022)

Multiparametric mapping in the diagnosis and management of cardiac transplant rejection: a prospective, histologically-validated study
por: Imran, Muhammad, et al.
Publicado: (2016)

Non-HLA Antibodies and Epitope Mismatches in Kidney Transplant Recipients With Histological Antibody-Mediated Rejection
por: Crespo, Marta, et al.
Publicado: (2021)

Treatment of Antibody-Mediated Rejection After Kidney Transplantation: Immunological Effects, Clinical Response, and Histological Findings
por: de Sousa, Marcos Vinicius, et al.
Publicado: (2020)

Histologic and Molecular Patterns in Responders and Non-responders With Chronic-Active Antibody-Mediated Rejection in Kidney Transplants
por: Sazpinar, Onur, et al.
Publicado: (2022)

An age-independent gene signature for monitoring acute rejection in kidney transplantation
por: Shaw, Brian I, et al.
Publicado: (2020)

Long-term CMV monitoring and chronic rejection in renal transplant recipients
por: Ishikawa, Shoko, et al.
Publicado: (2023)

The Pre-Transplant Non-HLA Antibody Burden Associates With the Development of Histology of Antibody-Mediated Rejection After Kidney Transplantation
por: Senev, Aleksandar, et al.
Publicado: (2022)

Alloimmune Risk Stratification for Kidney Transplant Rejection
por: Bestard, Oriol, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_20hdej559hmr21u14gtu2jp4pe